Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4139 Biotechnology

Not Yet Opened 12-18 16:00:00 EST

70.08

-0.54

-0.76%

High70.79	Low70.01	Vol659.09M
Open70.61	D1 Closing70.62	Amplitude1.10%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O17.29B	T/O Rate--	Tradable Shares0.00
P/B7.038401	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"Biotechnology","latestPrice":70.081215,"timestamp":1766091599999,"preClose":70.61826,"halted":0,"volume":659089975,"delay":0,"changeRate":-0.007605,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-0.537048,"latestTime":"12-18 16:00:00 EST","open":70.60811,"high":70.7889,"low":70.01107,"amount":17289181931.218266,"amplitude":0.011015,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766154600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":7.038401,"peRate":-123.871822,"turnoverRate":0.020318,"increases":227,"decrements":282,"flats":15,"marketCap":1819688613826,"floatMarketCap":1633054737378.25},"requestUrl":"/m/hq/s/BK4139/tweets","defaultTab":"tweets","newsList":[{"id":"2592166842","title":"Energy Fuels Inc. Qualifies US-Produced Dysprosium Oxide for Permanent Magnet Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2592166842","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592166842?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:15","pubTimestamp":1766142921,"startTime":"0","endTime":"0","summary":"Energy Fuels Inc. has announced a significant advancement in the U.S. rare earth supply chain with the successful production and qualification of high-purity dysprosium oxide at its White Mesa Mill in Utah. The company's dysprosium oxide, which achieved 99.9% purity, has passed initial quality assurance tests by a major South Korean automotive manufacturer for use in permanent magnets. Energy Fuels is the first U.S. company to have both \"light\" and \"heavy\" rare earth elements qualified for use in permanent magnet applications, a key milestone for national defense and industrial supply chains. The company plans to expand production to include terbium and potentially samarium oxides, with commercial-scale output of heavy rare earths expected as soon as the fourth quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL6JC88R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIXT","BK4156","BK4139","UUUU","BK4606"],"gpt_icon":0},{"id":"2592165228","title":"Pyxis Oncology, Inc. : H.c. Wainwright Raises Target Price to $7 From $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2592165228","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592165228?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:08","pubTimestamp":1766142537,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nAZN4RH4QG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PYXS","BK4139"],"gpt_icon":0},{"id":"2592165488","title":"Several top drugmakers to lower US prices for some drugs-sources","url":"https://stock-news.laohu8.com/highlight/detail?id=2592165488","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592165488?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:00","pubTimestamp":1766142000,"startTime":"0","endTime":"0","summary":"Several top drugmakers to lower US prices for some drugs-sourcesBy Michael Erman, Jarrett Renshaw and Patrick Wingrove","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nL1N3XO0QU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN.UK","AMGN","BMY","LU0052756011.USD","03165","GILD","LU0006306889.USD","BK4568","LU0965509283.SGD","SG9999011175.SGD","LU2491050154.USD","LU0820561909.HKD","SG9999015945.SGD","IE00BJJMRX11.SGD","LU0203347892.USD","MRK","LU1988902786.USD","LU1244550221.USD","LU0477156953.USD","LU0889565916.HKD","LU0972486137.USD","LU2236285917.USD","LU0029864427.USD","LU0997586432.USD","LU1037948897.HKD","LU2552382215.SGD","BK4139","REGN","BK4566","LU0882574055.USD","LU2461242641.AUD","LU0857590862.USD","LU1162221912.USD","LU0823399737.USD","LU2347655156.SGD","LU2133065610.SGD","LU0211326839.USD","LU1032955483.USD","SG9999015952.SGD","LU2237438978.USD","BK4592","JNJ","SGXZ31699556.SGD","ABBV","LU1066053197.SGD","IE00BVYPNW00.USD","LU0238689110.USD","LU1894683264.USD"],"gpt_icon":1},{"id":"2592630931","title":"Assessing Monte Rosa Therapeutics (GLUE) Valuation After Encouraging Phase 1/2 Prostate Cancer Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2592630931","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592630931?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:25","pubTimestamp":1766136338,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) just gave investors a fresh catalyst, sharing interim Phase 1/2 data showing 100% disease control and PSA responses in a key prostate cancer subgroup, along with plans for a follow up Phase 2 trial.\nSee our latest analysis for Monte Rosa Therapeutics.\nThat strength in the clinic has gone hand in hand with shifting sentiment in the stock, with a 150.08% 3 month share price return and 128.43% 1 year total shareholder return signaling powerful, still building...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/assessing-monte-rosa-therapeutics-glue-valuation-after-encou","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/assessing-monte-rosa-therapeutics-glue-valuation-after-encou","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","GLUE","DCF","BK4539"],"gpt_icon":0},{"id":"2592163037","title":"How Investors May Respond To Zai Lab (ZLAB) Advancing ZL-1503 Into Global Phase 1/1b Atopic Dermatitis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592163037","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592163037?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:21","pubTimestamp":1766136083,"startTime":"0","endTime":"0","summary":"Zai Lab Limited recently dosed the first participant in a global randomized, double-blind, placebo-controlled Phase 1/1b trial of ZL-1503, a potential first-in-class IL-13/IL-31R bispecific antibody for moderate-to-severe atopic dermatitis, following encouraging preclinical data presented at the 2025 EAACI Congress.\nThe internally discovered ZL-1503, designed to suppress both inflammatory and itch-related pathways with an extended half-life, could meaningfully broaden Zai Lab’s immunology...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zlab/zai-lab/news/how-investors-may-respond-to-zai-lab-zlab-advancing-zl-1503","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zlab/zai-lab/news/how-investors-may-respond-to-zai-lab-zlab-advancing-zl-1503","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4526","BK4548","BK4531","BK4139","BK4585","BK4211","ISBC","BK4588","ZLAB","LU2488822045.USD"],"gpt_icon":0},{"id":"2592157939","title":"AEON Credit Service (M)'s Profit Soars in Fiscal Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2592157939","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592157939?lang=en_us&edition=fundamental","pubTime":"2025-12-19 17:17","pubTimestamp":1766135822,"startTime":"0","endTime":"0","summary":"Aeon Credit Service's  profit attributable to owners jumped 40.6% annually to 99.5 million ringgit in the fiscal third quarter ended Nov. 30 from 70.8 million ringgit a year earlier.Earnings per share went up to 0.1798 ringgit from 0.1216 ringgit a year ago, according to a Thursday Malaysian bourse filing.Revenue increased 10.7% to 622.4 million ringgit from 562 million ringgit a year ago, the Malaysian lender said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4103","BK4588","BK4139","AEON","BK4220","BK4585"],"gpt_icon":0},{"id":"2592715230","title":"Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®","url":"https://stock-news.laohu8.com/highlight/detail?id=2592715230","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592715230?lang=en_us&edition=fundamental","pubTime":"2025-12-19 16:40","pubTimestamp":1766133600,"startTime":"0","endTime":"0","summary":"According to the settlement agreement, the proposed biosimilar to Eylea (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/19/3208323/0/en/Alvotech-and-Teva-Secure-U-S-Settlement-Date-for-AVT06-a-Proposed-Biosimilar-to-Eylea.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ58947870.SGD","SG9999004360.SGD","LU0441851309.USD","LU0516422440.USD","LU2045819591.USD","LU0572940350.SGD","LU2065171402.SGD","LU0516423174.USD","BK4551","BK4535","SG9999001135.SGD","LU0823039010.USD","SG9999002679.SGD","BK4554","SG9999013478.USD","LU0516423091.SGD","LU2065171311.SGD","BK4503","LU1048588211.SGD","LU2125910500.SGD","BK4085","LU0072462343.USD","BK4548","LU0589944569.HKD","SG9999002406.SGD","BK4585","LU0251143029.SGD","LU2152927971.USD","LU1242518931.SGD","LU0289960550.SGD","SG9999006266.SGD","BK4566","IE0034224299.USD","LU2065169927.USD","BK4139","BK4220","BK4097","LU0823038988.USD","ALVO","LU0499858438.USD","LU1839390173.USD","SG9999013486.USD","LU0345776255.USD","LU0516422366.SGD","LU0345775950.USD","LU1861217088.USD","IE0031814969.USD","LU0979878070.USD","SG9999002414.USD","LU0348788117.USD","LU0175139822.USD","SG9999005177.SGD","BK4588","IE00BD6J9T35.USD","LU1861220207.SGD","LU2238330802.EUR","SG9999002620.SGD","LU0532188223.SGD","LU2360107671.USD","LU2177674079.SGD","TEVA","SG9999014484.SGD","SG9999002604.SGD","LU0516422952.EUR","IE0001KFT4U8.USD","SG9999013460.SGD","LU0499858602.USD","LU2125910849.SGD","SG9999014492.USD","BK4581","LU0737861269.HKD","LU2008162690.USD","LU0264606111.USD","LU1242518857.USD","LU1770036033.HKD","LU0048573645.USD","LU0261945553.USD","LU2543165471.USD","LU0210637038.USD","LU2065170008.USD","LU0572939691.SGD"],"gpt_icon":0},{"id":"2592154719","title":"BRIEF-Alvotech and Teva Secure U.S. Settlement Date For AVT06","url":"https://stock-news.laohu8.com/highlight/detail?id=2592154719","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592154719?lang=en_us&edition=fundamental","pubTime":"2025-12-19 16:39","pubTimestamp":1766133570,"startTime":"0","endTime":"0","summary":"BRIEF-Alvotech and Teva Secure U.S. Settlement Date For AVT06Dec 19 (Reuters) - Alvotech SA ALVO.O:ALVOTECH AND TEVA SECURE U.S. SETTLEMENT DATE FOR AVT06, A PROPOSED BIOSIMILAR TO EYLEAALVOTECH SA - ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA5W8TV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4596","BK4585","TEVA","BK4566","LU1983299246.USD","ALVO","BK4139","BK4007","BK4557","BK4559","BK4584"],"gpt_icon":0},{"id":"2592182154","title":"Alvotech Sa - License Entry Date for Avt06 in U.S. Set for Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182154?lang=en_us&edition=fundamental","pubTime":"2025-12-19 16:30","pubTimestamp":1766133000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nTUA5W8TV7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALVO","BK4584","BK4596","LU1983299246.USD","BK4566","TEVA","BK4557","BK4559","BK4007","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2592156441","title":"Genenta Science CEO Pierluigi Paracchi Acquires 30,000 ADSs in Open-Market Purchases","url":"https://stock-news.laohu8.com/highlight/detail?id=2592156441","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592156441?lang=en_us&edition=fundamental","pubTime":"2025-12-19 15:30","pubTimestamp":1766129421,"startTime":"0","endTime":"0","summary":"Genenta Science S.p.A. announced that its Chief Executive Officer and Co-Founder, Pierluigi Paracchi, has acquired a total of 30,000 American Depositary Shares  of the company through open-market purchases. As of December 19, 2025, Mr. Paracchi owns an aggregate of 2,326,129 ADSs and ordinary shares, representing approximately 10% of Genenta's outstanding share capital. No sales of the company's securities by Mr. Paracchi have been reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genenta Science S.p.A. published the original content used to generate this news brief via GlobeNewswire  on December 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLb9q48t:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4139","SG9999014013.SGD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","GNTA","BK4585","SG9999014021.USD","SG9999014039.USD","LU2210149790.SGD","BK4588","SG9999014005.SGD","LU2210150020.SGD","LU2095319765.USD","LU0314104364.USD","NDAQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"1124158805","title":"Post-AI Rally: Four Defensive Stocks to Watch for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1124158805","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124158805?lang=en_us&edition=fundamental","pubTime":"2025-12-19 15:05","pubTimestamp":1766127946,"startTime":"0","endTime":"0","summary":"After significant gains, the AI-driven tech sector is on track for a third consecutive year of over 20% growth. However, December's divergent performance among tech stocks suggests narrowing...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","IE00B19Z3581.USD","IE00BFTCPJ56.SGD","BK4585","SG9999001176.SGD","LU2417539215.USD","IE00B2B36J28.USD","LU0289739699.SGD","BK4139","LU0417517546.SGD","BK4567","LU2324357040.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU2456880835.USD","SG9999013999.USD","IE00BZ9MQY76.HKD","LU0320765992.SGD","IE00BD4GTW91.USD","IE00BJT1NW94.SGD","LU2462157665.USD","BK4208","IE00B4R5TH58.HKD","LU1093756168.USD","LU0109394709.USD","IE00B19Z9P08.USD","LU0079474960.USD","LU1585245621.USD","PEG","LU0256863811.USD","IE00BD4GTT62.SGD","LU2362540622.SGD","LU0058720904.USD","IE0002270589.USD","LU1035775433.USD","LU1093756325.SGD","LU0823416689.USD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","IE00BMG7P587.USD","LU2362541273.HKD","IE00BMG7P819.SGD","EPS","BK4588","BK4533","LU1430594728.SGD","LU0061475181.USD","IE0009355771.USD","IE00BMG7P694.USD","LU1674673691.USD","LU2236285917.USD","IE00B894F039.SGD","IE00BD4GTV84.USD","LU0889565916.HKD","LU1674673428.USD","LU0234570918.USD","IE00BMG7P926.USD","LU1069344957.HKD","BK4532","LU2237438978.USD","SG9999001176.USD","LU1778281490.HKD","VRTX","LU0432979614.USD","LU2346227817.USD","IE00B19Z9Z06.USD"],"gpt_icon":0},{"id":"2592130053","title":"Nuvalent Inc : JP Morgan Cuts Target Price to $145 From $147","url":"https://stock-news.laohu8.com/highlight/detail?id=2592130053","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592130053?lang=en_us&edition=fundamental","pubTime":"2025-12-19 13:34","pubTimestamp":1766122483,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XP012:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NUVL","BK4539"],"gpt_icon":0},{"id":"2592715311","title":"Beam Therapeutics (BEAM): Reassessing Valuation After New BEACON risto-cel Data in Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2592715311","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592715311?lang=en_us&edition=fundamental","pubTime":"2025-12-19 13:20","pubTimestamp":1766121655,"startTime":"0","endTime":"0","summary":"Beam Therapeutics (BEAM) just updated investors on new safety and efficacy results from its BEACON Phase 1/2 trial in sickle cell disease, and the stock is reacting to what this means for future commercialization.\nSee our latest analysis for Beam Therapeutics.\nThe latest BEACON update lands after a choppy year, with a 24.74% 1 month share price return but a 1 year total shareholder return of negative 9.79%. This suggests that near term momentum is improving even as longer term holders remain...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-reassessing-valuation-after-new-beaco","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/beam-therapeutics-beam-reassessing-valuation-after-new-beaco","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BEAM","BK4585","BK4505","BK4611","BK4535","BK4556","BK4588"],"gpt_icon":0},{"id":"2592413797","title":"Insmed Inc : Truist Securities Assumes Coverage With Buy Rating; Target Price $205 VS $214","url":"https://stock-news.laohu8.com/highlight/detail?id=2592413797","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592413797?lang=en_us&edition=fundamental","pubTime":"2025-12-19 12:25","pubTimestamp":1766118306,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XO0UD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","BK4139","LU0053671581.USD","INSM"],"gpt_icon":0},{"id":"2592137560","title":"Madrigal Pharmaceuticals Inc : Piper Sandler Raises Target Price to $900 From $540","url":"https://stock-news.laohu8.com/highlight/detail?id=2592137560","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592137560?lang=en_us&edition=fundamental","pubTime":"2025-12-19 12:16","pubTimestamp":1766117774,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nFWN3XO12O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","MDGL","BK4588","BK4139"],"gpt_icon":0},{"id":"2592813282","title":"CARsgen Therapeutics Extends Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2592813282","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592813282?lang=en_us&edition=fundamental","pubTime":"2025-12-19 11:36","pubTimestamp":1766115405,"startTime":"0","endTime":"0","summary":"CARsgen Therapeutics  extended a previously announced share repurchase program, according to a Hong Kong bourse filing Thursday.Shares of the cell therapy developer gained over 1% in morning trade Friday.The program will last until the company's next annual general meeting.CARsgen plans to repurchase a total of 5% of its issued share capital from the open market under the program.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1585","BK4539","BK4139","LENZ","BK1574","BK1161","BK4007","02171","BK1587"],"gpt_icon":0},{"id":"2592136767","title":"Amplia Therapeutics Enters Second Phase of Research Collaboration with South Korean Preclinical Drug Screening Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2592136767","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592136767?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:54","pubTimestamp":1766109250,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  entered into the second phase of a research collaboration with South Korean preclinical drug screening company Next & Bio, according to a Friday Australian bourse filing.The firms are collaborating on investigating the ability of Amplia's FAK inhibitors to suppress the growth of patient-derived pancreatic cancer cells that possess genetic mutations in the kRAS gene, which are known to be present in over 90% of pancreatic cancers.Amplia's FAK inhibitor narmafotinib showed promising activity in initial tests, per the filing. Further studies investigating the activity of a combination of narmafotinib with known inhibitors of the mutant kRAS gene will be conducted.Its shares rose 2% in recent trading on Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","BK4139","BK7067","ATX.AU","LENZ"],"gpt_icon":0},{"id":"2592113135","title":"PYC Therapeutics Says Safety Review Committee Confirms Safety of Polycystic Kidney Disease Drug Candidate Dose in Phase 1a/1b Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2592113135","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592113135?lang=en_us&edition=fundamental","pubTime":"2025-12-19 09:17","pubTimestamp":1766107027,"startTime":"0","endTime":"0","summary":"PYC Therapeutics (ASX:PYC) said that a safety review committee governing the phase 1a/1b study confirmed that single doses of its PYC-003 drug candidate, for the treatment of the underlying causes of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK7067","BK4139","BK4539","BK4007","PYC.AU"],"gpt_icon":0},{"id":"2592133277","title":"Director Daniel Allen Gold Reports Disposal of Roivant Sciences Ltd. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592133277","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592133277?lang=en_us&edition=fundamental","pubTime":"2025-12-19 08:54","pubTimestamp":1766105698,"startTime":"0","endTime":"0","summary":"Daniel Allen Gold, Director, reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLbdkmXN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2592613311","title":"QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2592613311","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592613311?lang=en_us&edition=fundamental","pubTime":"2025-12-19 08:42","pubTimestamp":1766104942,"startTime":"0","endTime":"0","summary":"QVT Financial LP reported a disposal of common shares of Roivant Sciences Ltd. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL2smmKl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"QVT Financial LP Reports Disposal of Roivant Sciences Ltd. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0184},{"period":"1month","weight":0.0248},{"period":"3month","weight":0.0192},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.1538},{"period":"ytd","weight":0.1542}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4139","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biotechnology,BK4139,Biotechnology股票,Biotechnology股票老虎,Biotechnology股票老虎国际,Biotechnology行情,Biotechnology股票行情,Biotechnology股价,Biotechnology股市,Biotechnology股票价格,Biotechnology股票交易,Biotechnology股票购买,Biotechnology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biotechnology(BK4139),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biotechnology(BK4139) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction